Bristol-Myers Squibb’s Yervoy wins Prix Galien discovery of the decade award

Bristol-Myers Squibb's recombinant human monoclonal antibody Yervoy has won the Prix Galien USA Discovery of the Decade biotech award.

Commemorating the tenth anniversary of the Prix Galien awards, the prize was presented to Bristol-Myers Squibb following deliberation by a scientific committee including several Nobel Laureates.

Yervoy previously received the best biotechnology product award following its initial approval in 2012. The development of the drug has been recognised as a significant milestone in the evolution of immuno-oncology.

The drug is now approved in more than 50 countries for treatment of unresectable or metastatic melanoma.

Dr Francis Cuss, chief scientific officer and executive vice-president of research and development at Bristol-Myers Squibb, said: "We are honored to receive this special recognition for Yervoy, an agent that ushered in what can easily be described as a historical time in cancer research."

This is the third Prix Galien honor received by Bristol-Myers Squibb, which remains the only company to receive the Prix Galien USA best biotechnology product award for two immuno-oncology agents.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.